N. Gaidzik

发表

Synthetic antitumor vaccines containing MUC1 glycopeptides with two immunodominant domains-induction of a strong immune response against breast tumor tissues.

H. Sinn, E. Schmitt, H. Kunz, 2011, Angewandte Chemie.

Fully synthetic vaccines consisting of tumor-associated MUC1 glycopeptides and a lipopeptide ligand of the Toll-like receptor 2.

E. Schmitt, Yan‐Mei Li, H. Kunz, 2010, Angewandte Chemie.

A synthetic vaccine consisting of a tumor-associated sialyl-T(N)-MUC1 tandem-repeat glycopeptide and tetanus toxoid: induction of a strong and highly selective immune response.

E. Schmitt, H. Kunz, D. Kowalczyk, 2009, Angewandte Chemie.

Synthetic vaccines consisting of tumor-associated MUC1 glycopeptide antigens and a T-cell epitope for the induction of a highly specific humoral immune response.

E. Schmitt, H. Kunz, Ulrika Westerlind, 2008, Angewandte Chemie.

A Synthetic Glycopeptide Vaccine for the Induction of a Monoclonal Antibody that Differentiates between Normal and Tumor Mammary Cells and Enables the Diagnosis of Human Pancreatic Cancer.

P. Flemming, E. Schmitt, H. Kunz, 2016, Angewandte Chemie.

The development of synthetic antitumour vaccines from mucin glycopeptide antigens.

H. Kunz, Ulrika Westerlind, N. Gaidzik, 2013, Chemical Society reviews.

Synthetic antitumor vaccines from tetanus toxoid conjugates of MUC1 glycopeptides with the Thomsen-Friedenreich antigen and a fluorine-substituted analogue.

E. Schmitt, H. Kunz, D. Kowalczyk, 2010, Angewandte Chemie.

Organochromium complexes as catalysts for the carboalumination of unactivated terminal olefins.

M. Enders, S. Doye, N. Gaidzik, 2009, Dalton transactions.

Reduced Breast Tumor Growth after Immunization with a Tumor-Restricted MUC1 Glycopeptide Conjugated to Tetanus Toxoid

Marcus Schmidt, P. Besenius, E. Schmitt, 2018, Cancer Immunology Research.

Tumor-associated MUC1 tandem-repeat glycopeptide microarrays to evaluate serum- and monoclonal-antibody specificity.

H. Waldmann, C. Niemeyer, E. Schmitt, 2009, Angewandte Chemie.

The development of synthetic antitumour vaccines from mucin glycopeptide antigens.

H. Kunz, Ulrika Westerlind, N. Gaidzik, 2013, Chemical Society reviews.